Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Tatabanya – page 18

630 clinical trials in Tatabanya, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Tatabanya at a glance
630
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

630 trials in Tatabanya

Open in trial search

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Rheumatoid arthritis

Not yet recruiting

Study comparing MB04 (etanercept biosimilar) with Enbrel in patients with moderate to severe rheumatoid arthritis who are taking methotrexate

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:Mabxience Research S.L.

Rheumatoid arthritis

Not yet recruiting

Study on the Effectiveness and Safety of Tocilizumab and Methotrexate for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Dr Reddy's Laboratories Limited

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Curateq Biologics Private Limited

Dermatitis atopic

Not yet recruiting

Study on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Partial seizures

Not yet recruiting

Long‑Term Safety and Effectiveness of 3-(7‑chloro‑1H‑indazol‑5‑yl)-2,5‑bis(trifluoromethyl)-3H‑imidazo[4,5‑b]pyridine in Adults with Refractory Focal Onset Epilepsy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Rapport Therapeutics Inc.

Colitis ulcerative+1

Not yet recruiting

Study of ABBV-701 and Risankizumab Combination vs Monotherapy in Adults with Moderately to Severely Active Crohn’s Disease or Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Colitis ulcerative+1

Not yet recruiting

Study of risankizumab plus anti‑α4β7 integrin antibody versus each alone in adults with moderately to severely active Crohn’s disease or ulcerative colitis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Type 2 diabetes mellitus

Not yet recruiting

Phase 3 Study of Maridebart Cafraglutide versus Semaglutide as Add‑on to Metformin (± SGLT‑2 Inhibitor) in Adults with Type 2 Diabetes Not Controlled by Metformin

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Amgen Inc.

Cardiovascular disorder+2

Not yet recruiting

Phase III Study Evaluating Efficacy and Safety of Petrelintide in Participants with Overweight or Obesity and Established Cardiovascular Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Petrelintide
  • Sponsor:F. Hoffmann-La Roche AG

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Prostate cancer metastatic

Not yet recruiting

Study of saruparib plus AR inhibitor drug combination in men with metastatic hormone‑sensitive prostate cancer previously treated with docetaxel or Lu‑PSMA and PSA ≥0.2 ng/mL

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Astrazeneca AB

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Tatabanya

What the registry says about research in the country

01 Oncology Studies

Comprehensive research focusing on breast cancer, prostate cancer, and lung cancer treatments, evaluating novel therapeutic combinations and targeted approaches.

  • Breast Cancer Research: HER2-negative and hormone receptor-positive treatments
  • NSCLC Studies: Advanced therapy combinations
  • Prostate Cancer Trials: Metastatic disease management

Multiple studies exploring immunotherapy combinations and targeted treatments for various cancer stages.

02 Inflammatory Conditions

Innovative clinical trials investigating treatments for Crohn's Disease and chronic rhinosinusitis, focusing on long-term management and symptom control.

  • Gastrointestinal Studies: Advanced therapies for IBD
  • Respiratory Research: Novel treatments for chronic sinusitis
  • Long-term Safety Evaluations

Research emphasizing both immediate efficacy and sustained therapeutic benefits.

03 Neurological Disorders

Focused research on Parkinson's Disease treatment options, evaluating long-term safety and effectiveness of novel therapeutic approaches.

  • Movement Disorder Studies
  • Long-term Treatment Evaluations
  • Safety and Tolerability Assessments

Studies aimed at improving quality of life and disease management for patients with neurological conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.